Bayer unveils latest radiology offerings and RAD-AID international collaboration at RSNA

November 29, 2016
Indianola, PA, November 29, 2016 – Bayer announced today the full launch of its U.S. Radiology myORDERS eCommerce website at the 2016 Radiological Society of North America (RSNA) Annual Meeting in Chicago. The launch is part of Bayer’s RSNA activities showcasing its full suite of radiology solutions for contrast media, magnetic resonance (MR), computed tomography (CT) and informatics. In addition, Bayer has established a new collaboration with the non-profit organization RAD-AID International to help advance its mission to increase and improve radiology technology and medical imaging in developing and impoverished countries around the world.

The myORDERS digital ordering platform – one of the first of its kind in radiology – will allow customers to place and track shipments of radiology-related disposables, such as syringes and tubing, online. Customers also will be able to use the site to access Bayer’s full catalog of radiology supply offerings. The site will provide customers expanded control over their orders and help limit the potential for human error associated with manual data entry.

“We’ve heard from our radiology customers that they want to streamline how they engage with us and are eager for new ways to connect digitally,” said Dennis Durmis, Head of Commercial Operations, Radiology Americas at Bayer. “myORDERS is the first of multiple eCommerce tools that Bayer is building as part of our ongoing commitment to meeting the needs of hospitals, radiologists and patients. We will continue to move forward with technologies that improve our customers’ workflow, always with a focus on what will be best for serving the patient.”

As part of its long standing commitment to the radiology community, Bayer’s ongoing collaboration with RAD-AID will help support training and resourcing for radiology services in hospitals in low-resource regions around the world. According to the World Health Organization (WHO), approximately half of the world’s population does not have access to radiology technologies such as x-rays, MR imaging (MRI) or CT scans and is at risk for widespread losses and deaths that could potentially be avoided or treated, if radiology were available.i.ii

“This collaboration between RAD-AID and Bayer substantially reinforces global radiology charitable efforts for medically underserved populations of the world by leveraging RAD-AID's international volunteer networks and on-site in-country hospital teams with Bayer's expertise and resources in radiology health services,” said Daniel J. Mollura, MD, President and CEO of RAD-AID International.

About Bayer’s Radiology Business
As a true life science company, Bayer is a global industry leader in radiology with a strong presence across all regions worldwide. Bayer provides radiologists with a portfolio of diagnostic imaging products and services along the Radiology workflow and engages collaboratively with original equipment manufacturers (OEMs) of diagnostic imaging scanners and healthcare IT partners. Bayer has been committed to radiology for more than 100 years and continues to partner with radiologists to guide diagnostic care.

About RAD-AID International
RAD-AID International (501c3 nonprofit) has received awards and recognition from the World Health Organization, American College of Radiology, American Society of Radiologic Technologists, American Medical Association, Canadian Association of Medical Radiation Technologists, and the Clinton Global Initiative for innovative health solutions serving indigent populations. For more information, go to

Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2015, the Group employed around 117,000 people and had sales of EUR 46.3 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.3 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to